Inogen, Inc. (INGN)
NASDAQ: INGN · Real-Time Price · USD
6.44
-0.18 (-2.72%)
At close: Jun 11, 2025, 4:00 PM
6.45
+0.01 (0.16%)
After-hours: Jun 11, 2025, 4:00 PM EDT

Company Description

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally.

The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

The company offers Inogen One and Inogen Rove, an ambulatory solutions for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories.

It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

Inogen, Inc.
Inogen logo
Country United States
Founded 2001
IPO Date Feb 14, 2014
Industry Medical Devices
Sector Healthcare
Employees 766
CEO Kevin R. Smith

Contact Details

Address:
859 Ward Drive
Goleta, California 93111
United States
Phone 805 562 0500
Website inogen.com

Stock Details

Ticker Symbol INGN
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001294133
CUSIP Number 45780L104
ISIN Number US45780L1044
SIC Code 3842

Key Executives

Name Position
Kevin R. M. Smith President, Chief Executive Officer and Director
Michael J. Bourque CPA Executive Vice President, Chief Financial Officer and Corporate Treasurer
Kevin P. Smith General Counsel, Secretary and Executive Vice President of Business Development
Grgoire Ramade Executive Vice President and Chief Commercial Officer
Philip Corrin Senior Vice President of Operations and Supply Chain
Ryan Peterson Associate Director of Investor Relations
Jennifer Yi Boyer Executive Vice President and Chief Human Resources Officer
Dr. Krishna Jhaveri Chief Medical Officer
Paul Andreassi Senior Vice President of Quality and Regulatory Affairs
Adrien Mithalal Senior Vice President of Research and Development

Latest SEC Filings

Date Type Title
May 29, 2025 SD Form - SD
May 20, 2025 S-8 Securities to be offered to employees in employee benefit plans
May 19, 2025 8-K Current Report
May 15, 2025 SCHEDULE 13G/A Filing
May 15, 2025 SCHEDULE 13G/A Filing
May 8, 2025 10-Q Quarterly Report
May 7, 2025 8-K Current Report
Mar 27, 2025 ARS Filing
Mar 27, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 27, 2025 DEF 14A Other definitive proxy statements